From GlobeNewswire: 2025-05-13 08:00:00

Quoin Pharmaceuticals continues to make progress in late-stage studies for Netherton Syndrome, with positive clinical data for both adult and pediatric patients. Clear visual evidence of the mechanism of action for QRX003 was provided. The patent portfolio has been expanded to support pipeline growth, and the NETHERTON NOW advocacy initiative has been launched.

In the first quarter of 2025, Quoin reported compelling data from multiple QRX003 studies, showing almost complete skin healing and elimination of pruritus in Netherton patients. The company also expanded its patent portfolio to cover novel formulations for rare skin diseases and launched an advocacy initiative. Financially, Quoin had approximately $11.6 million in cash and reported a net loss of $3.8 million for the quarter.

Key milestones in early 2025 include positive data from adult and pediatric studies, with whole-body treatment leading to significant improvements for patients with Netherton Syndrome. The company also launched the NETHERTON NOW awareness campaign and filed patents for topical rapamycin formulations targeting rare skin diseases. Quoin’s cash position is expected to support operations into the first quarter of 2026.



Read more at GlobeNewswire:: Quoin Pharmaceuticals Provides Corporate Update and